lymphoblastic

Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement.

Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR. Methotrexate has antimetabolic, antitumor, and immunosuppressive activities, and is commonly used in rheumatoid arthritis and various tumors.

Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.

Methotrexate disodium is an tetrahydrofolate dehydrogenase inhibitor

EB-3D is a potent and selective choline kinase alpha 1 (ChoKα1) inhibitor (IC50: 1 μM) with anti-cancer activity.

NL-1, a mitoNEET inhibitor, exhibits antileukemic effects.

Pheniramine maleate (Trimetose), an alkylamine derivative with antihistaminic and vasodilatory properties, binds to histamine H1 receptors, thereby inhibiting phospholipase A2 and production of the endothelium-derived relaxing factor, nitric oxide.

Nelarabine (GW 506U78) is a purine nucleoside analog and DNA synthesis inhibitor with IC50 from 0.067-2.15 μM in tumor cells.

L-Asparaginase (L-ASNase) (L-ASNase), a hydrolase that catalyzes the conversion of L-asparagine, used in acute lymphoblastic leukemia treatment.Asparaginase is an enzyme that is used as a medication. As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin.

(Rac)-SHIN2, a serine hydroxymethyltransferase (SHMT) inhibitor, enhances NOTCH1-driven in vivo survival of primary T-ALL in mice and is useful for studying T-cell acute lymphoblastic leukemia (T-ALL).

USP7-IN-4(USP7 inhibitor ALM4) is a non-competitive, potent and selective inhibitor of USP7 (ubiquitin-specific protease 7) with an IC50 = 6 nM, up-regulates p53 and p21, down-regulates MDM2, increases the level of ubiquitination of MDM2, and exhibits anti-proliferative activity in a variety of cancer cell lines, with an EC50 = 2.0 nM in RS4;11 (acute lymphoblastic leukemia cell line) .

Daunorubicin is an anthracycline antibiotic and topoisomerase II inhibitor with anticancer activity, inhibiting DNA and RNA synthesis, and is commonly used to treat acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL).

CAD204520 functions as an inhibitor of SERCA (IC50 = 0.34 μM), specifically targeting mutations in the wild-type NOTCH1 protein associated with T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL).

Revumenib (also known as SNDX-5613) is an effective and selective Menin-MLL inhibitor. It is primarily used for the study of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

AcBut-N-Ac-γ-Calicheamicin serves as a toxic molecule for ADCs, inducing cell cycle arrest and apoptosis (Apoptosis) by causing DNA double-strand breaks. Primarily utilized in the synthesis of antibody-drug conjugates (ADC), it holds promise for cancer research, particularly in studies related to acute lymphoblastic leukemia (ALL) and other hematological malignancies.

PKN3-IN-1 (compound 16) inhibits PKN3 (serine/threonine-protein kinase N3) and GAK (cyclin G-associated kinase) with an IC50 of 0.014 μM and a Ki of 0.0044 μM. PKN3-IN-1 is a potential tool compound for investigating the cell biology of PKN3 and its role in pancreatic and prostate cancers, as well as T-cell acute lymphoblastic leukemia.

Proteasome-IN-7 (Compound 6f) is a macrolactam-based epoxyketone proteasome inhibitor with an IC50 value of 37.92 nM against the 20S proteasome ChT-L subunit. It exhibits potent antiproliferative effects on multiple myeloma, acute lymphoblastic leukemia, and non-small cell lung cancer.

Metanilic acid, an anti-cancer drug, is used to treat several malignancies including choriocarcinoma and pediatric acute lymphoblastic leukemia.

4'-Ethynyl-2'-deoxycytidine is an anticancer nucleoside used in research on acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Lck-IN-3 (compound 7m) is an LCK inhibitor that targets acute lymphoblastic leukemia (ALL) by inhibiting LCK phosphorylation. Lck-IN-3 can induce cell cycle arrest at the G2/M phase, leading to apoptosis in ALL cells.

SJ45566 is an effective, orally active LCK PROTAC degrader with a DC50 value of 1.21 nM, suitable for research in acute T-cell lymphoblastic leukemia.

KI-TOX-A3 is a selective protein-protein interaction (PPI) inhibitor targeting the TOX protein, with an IC50 value of 0.51 μM for the TOX-KAT7 interaction. It promotes proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses CD8+ T cell exhaustion, and inhibits proliferation of T-cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 holds potential for research in hematological malignancies, including T-ALL.

I3IN-002 is a small molecule inhibitor targeting the RNA-binding protein IGF2BP3, with an IC50 value of approximately 2 μM in SEM cells. It disrupts the interaction with m6A-modified mRNA, destabilizing target genes (such as CDK6, MYC, and BCL2), thereby inhibiting the growth of leukemia cells, inducing cell cycle arrest, and promoting apoptosis. I3IN-002 shows potential for research in B-cell acute lymphoblastic leukemia.

Lckdegrader-1 (Compound 17) is a molecular glue degrader that targets lymphocyte-specific protein tyrosine kinase (LCK) with a DC50 of 23.1 nM. It holds potential for research in T-cell acute lymphoblastic leukemia (T-ALL).